268 related articles for article (PubMed ID: 30307508)
21. Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures.
Haynes P; Kernan K; Zhou SL; Miller DG
Skelet Muscle; 2017 Jun; 7(1):13. PubMed ID: 28637492
[TBL] [Abstract][Full Text] [Related]
22. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy.
Jagannathan S
Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166367. PubMed ID: 35158020
[TBL] [Abstract][Full Text] [Related]
23. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
Banerji CRS; Zammit PS
Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
[TBL] [Abstract][Full Text] [Related]
24. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
[TBL] [Abstract][Full Text] [Related]
25. MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.
Wang LH; Friedman SD; Shaw D; Snider L; Wong CJ; Budech CB; Poliachik SL; Gove NE; Lewis LM; Campbell AE; Lemmers RJFL; Maarel SM; Tapscott SJ; Tawil RN
Hum Mol Genet; 2019 Feb; 28(3):476-486. PubMed ID: 30312408
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.
Vanderplanck C; Tassin A; Ansseau E; Charron S; Wauters A; Lancelot C; Vancutsem K; Laoudj-Chenivesse D; Belayew A; Coppée F
Skelet Muscle; 2018 Jan; 8(1):2. PubMed ID: 29329560
[TBL] [Abstract][Full Text] [Related]
27. Cellular and animal models for facioscapulohumeral muscular dystrophy.
DeSimone AM; Cohen J; Lek M; Lek A
Dis Model Mech; 2020 Oct; 13(10):. PubMed ID: 33174531
[TBL] [Abstract][Full Text] [Related]
28. An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy.
Cowley MV; Pruller J; Ganassi M; Zammit PS; Banerji CRS
Elife; 2023 May; 12():. PubMed ID: 37184373
[TBL] [Abstract][Full Text] [Related]
29. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.
Lu-Nguyen N; Malerba A; Herath S; Dickson G; Popplewell L
Hum Mol Genet; 2021 Jul; 30(15):1398-1412. PubMed ID: 33987655
[TBL] [Abstract][Full Text] [Related]
30. Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD.
Krom YD; Thijssen PE; Young JM; den Hamer B; Balog J; Yao Z; Maves L; Snider L; Knopp P; Zammit PS; Rijkers T; van Engelen BG; Padberg GW; Frants RR; Tawil R; Tapscott SJ; van der Maarel SM
PLoS Genet; 2013 Apr; 9(4):e1003415. PubMed ID: 23593020
[TBL] [Abstract][Full Text] [Related]
31. Testing the effects of FSHD candidate gene expression in vertebrate muscle development.
Wuebbles RD; Long SW; Hanel ML; Jones PL
Int J Clin Exp Pathol; 2010 Mar; 3(4):386-400. PubMed ID: 20490329
[TBL] [Abstract][Full Text] [Related]
32. Dysregulation of 4q35- and muscle-specific genes in fetuses with a short D4Z4 array linked to facio-scapulo-humeral dystrophy.
Broucqsault N; Morere J; Gaillard MC; Dumonceaux J; Torrents J; Salort-Campana E; Maues De Paula A; Bartoli M; Fernandez C; Chesnais AL; Ferreboeuf M; Sarda L; Dufour H; Desnuelle C; Attarian S; Levy N; Nguyen K; Magdinier F; Roche S
Hum Mol Genet; 2013 Oct; 22(20):4206-14. PubMed ID: 23777630
[TBL] [Abstract][Full Text] [Related]
33. Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models.
Nunes AM; Ramirez M; Jones TI; Jones PL
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34338285
[TBL] [Abstract][Full Text] [Related]
34. Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy.
Lu-Nguyen N; Malerba A; Antoni Pineda M; Dickson G; Popplewell L
Hum Gene Ther; 2022 Sep; 33(17-18):923-935. PubMed ID: 35078334
[TBL] [Abstract][Full Text] [Related]
35. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
Banerji CRS; Panamarova M; Hebaishi H; White RB; Relaix F; Severini S; Zammit PS
Nat Commun; 2017 Dec; 8(1):2152. PubMed ID: 29255294
[TBL] [Abstract][Full Text] [Related]
36. Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene.
Himeda CL; Debarnot C; Homma S; Beermann ML; Miller JB; Jones PL; Jones TI
Mol Cell Biol; 2014 Jun; 34(11):1942-55. PubMed ID: 24636994
[TBL] [Abstract][Full Text] [Related]
37. Large family cohorts of lymphoblastoid cells provide a new cellular model for investigating facioscapulohumeral muscular dystrophy.
Jones TI; Himeda CL; Perez DP; Jones PL
Neuromuscul Disord; 2017 Mar; 27(3):221-238. PubMed ID: 28161093
[TBL] [Abstract][Full Text] [Related]
38. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T
Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777
[TBL] [Abstract][Full Text] [Related]
39. The prospects of targeting DUX4 in facioscapulohumeral muscular dystrophy.
Bouwman LF; van der Maarel SM; de Greef JC
Curr Opin Neurol; 2020 Oct; 33(5):635-640. PubMed ID: 32796277
[TBL] [Abstract][Full Text] [Related]
40. DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation.
Banerji CRS; Panamarova M; Zammit PS
Hum Mol Genet; 2020 Aug; 29(14):2285-2299. PubMed ID: 32242220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
